German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Institute of Biochemistry and Molecular Biology, University of Bonn, Bonn, Germany.
J Neurochem. 2020 Mar;152(6):710-726. doi: 10.1111/jnc.14870. Epub 2019 Oct 21.
Increasing evidence suggests that both synaptic loss and neuroinflammation constitute early pathologic hallmarks of Alzheimer's disease. A downstream event during inflammatory activation of microglia and astrocytes is the induction of nitric oxide synthase type 2, resulting in an increased release of nitric oxide and the post-translational S-nitrosylation of protein cysteine residues. Both early events, inflammation and synaptic dysfunction, could be connected if this excess nitrosylation occurs on synaptic proteins. In the long term, such changes could provide new insight into patho-mechanisms as well as biomarker candidates from the early stages of disease progression. This study investigated S-nitrosylation in synaptosomal proteins isolated from APP/PS1 model mice in comparison to wild type and NOS2 mice, as well as human control, mild cognitive impairment and Alzheimer's disease brain tissues. Proteomics data were obtained using an established protocol utilizing an isobaric mass tag method, followed by nanocapillary high performance liquid chromatography tandem mass spectrometry. Statistical analysis identified the S-nitrosylation sites most likely derived from an increase in nitric oxide (NO) in dependence of presence of AD pathology, age and the key enzyme NOS2. The resulting list of candidate proteins is discussed considering function, previous findings in the context of neurodegeneration, and the potential for further validation studies.
越来越多的证据表明,突触丧失和神经炎症构成了阿尔茨海默病的早期病理特征。小胶质细胞和星形胶质细胞炎症激活的下游事件是诱导一氧化氮合酶 2 的产生,导致一氧化氮的释放增加和蛋白质半胱氨酸残基的翻译后 S-亚硝基化。如果这种过量的亚硝化发生在突触蛋白上,那么早期的炎症和突触功能障碍事件就可能有关联。从疾病进展的早期阶段来看,这些变化可能为病理机制以及生物标志物候选物提供新的见解。本研究比较了 APP/PS1 模型小鼠与野生型和 NOS2 小鼠以及人类对照、轻度认知障碍和阿尔茨海默病脑组织中分离的突触蛋白中的 S-亚硝基化。使用基于等压质量标签方法的既定方案获得蛋白质组学数据,然后进行纳米毛细管高效液相色谱串联质谱分析。统计分析确定了最有可能源自一氧化氮(NO)增加的 S-亚硝基化位点,这取决于 AD 病理学、年龄和关键酶 NOS2 的存在。考虑到功能、神经退行性变背景下的先前发现以及进一步验证研究的潜力,对候选蛋白进行了讨论。